BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 17466614)

  • 1. PTH has the potential to rescue disturbed bone growth in achondroplasia.
    Ueda K; Yamanaka Y; Harada D; Yamagami E; Tanaka H; Seino Y
    Bone; 2007 Jul; 41(1):13-8. PubMed ID: 17466614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTHrP rescues ATDC5 cells from apoptosis induced by FGF receptor 3 mutation.
    Yamanaka Y; Tanaka H; Koike M; Nishimura R; Seino Y
    J Bone Miner Res; 2003 Aug; 18(8):1395-403. PubMed ID: 12929929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like growth factor-1 rescues the mutated FGF receptor 3 (G380R) expressing ATDC5 cells from apoptosis through phosphatidylinositol 3-kinase and MAPK.
    Koike M; Yamanaka Y; Inoue M; Tanaka H; Nishimura R; Seino Y
    J Bone Miner Res; 2003 Nov; 18(11):2043-51. PubMed ID: 14606518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent PTH (1-34) injection rescues the retarded skeletal development and postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia.
    Xie Y; Su N; Jin M; Qi H; Yang J; Li C; Du X; Luo F; Chen B; Shen Y; Huang H; Xian CJ; Deng C; Chen L
    Hum Mol Genet; 2012 Sep; 21(18):3941-55. PubMed ID: 22634226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed bone age due to a dual effect of FGFR3 mutation in Achondroplasia.
    Pannier S; Mugniery E; Jonquoy A; Benoist-Lasselin C; Odent T; Jais JP; Munnich A; Legeai-Mallet L
    Bone; 2010 Nov; 47(5):905-15. PubMed ID: 20673820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice.
    Garcia S; Dirat B; Tognacci T; Rochet N; Mouska X; Bonnafous S; Patouraux S; Tran A; Gual P; Le Marchand-Brustel Y; Gennero I; Gouze E
    Sci Transl Med; 2013 Sep; 5(203):203ra124. PubMed ID: 24048522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene.
    Matsushita M; Hasegawa S; Kitoh H; Mori K; Ohkawara B; Yasoda A; Masuda A; Ishiguro N; Ohno K
    Endocrinology; 2015 Feb; 156(2):548-54. PubMed ID: 25456072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model.
    Jonquoy A; Mugniery E; Benoist-Lasselin C; Kaci N; Le Corre L; Barbault F; Girard AL; Le Merrer Y; Busca P; Schibler L; Munnich A; Legeai-Mallet L
    Hum Mol Genet; 2012 Feb; 21(4):841-51. PubMed ID: 22072392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular basis for the treatment of achondroplasia.
    Yamanaka Y; Ueda K; Seino Y; Tanaka H
    Horm Res; 2003; 60 Suppl 3():60-4. PubMed ID: 14671399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parathyroid hormone receptor type 1/Indian hedgehog expression is preserved in the growth plate of human fetuses affected with fibroblast growth factor receptor type 3 activating mutations.
    Cormier S; Delezoide AL; Benoist-Lasselin C; Legeai-Mallet L; Bonaventure J; Silve C
    Am J Pathol; 2002 Oct; 161(4):1325-35. PubMed ID: 12368206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.
    Harada D; Yamanaka Y; Ueda K; Nishimura R; Morishima T; Seino Y; Tanaka H
    Bone; 2007 Aug; 41(2):273-81. PubMed ID: 17561467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of fibroblast growth factor receptor 3 by fibroblast growth factor 2 in cultured chick embryo chondrocytes.
    Suh JY; Kim YS; Park JW; Sonn JK; Kim WT
    Cell Biol Int; 2005 Mar; 29(3):203-12. PubMed ID: 15878293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of FGFR3 with the G380R achondroplasia mutation inhibits proliferation and maturation of CFK2 chondrocytic cells.
    Henderson JE; Naski MC; Aarts MM; Wang D; Cheng L; Goltzman D; Ornitz DM
    J Bone Miner Res; 2000 Jan; 15(1):155-65. PubMed ID: 10646125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maternal administration of meclozine for the treatment of foramen magnum stenosis in transgenic mice with achondroplasia.
    Matsushita M; Mishima K; Esaki R; Ishiguro N; Ohno K; Kitoh H
    J Neurosurg Pediatr; 2017 Jan; 19(1):91-95. PubMed ID: 27767902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skeletal dysplasia and defective chondrocyte differentiation by targeted overexpression of fibroblast growth factor 9 in transgenic mice.
    Garofalo S; Kliger-Spatz M; Cooke JL; Wolstin O; Lunstrum GP; Moshkovitz SM; Horton WA; Yayon A
    J Bone Miner Res; 1999 Nov; 14(11):1909-15. PubMed ID: 10571691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype.
    Murakami S; Balmes G; McKinney S; Zhang Z; Givol D; de Crombrugghe B
    Genes Dev; 2004 Feb; 18(3):290-305. PubMed ID: 14871928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGFR3 down-regulates PTH/PTHrP receptor gene expression by mediating JAK/STAT signaling in chondrocytic cell line.
    Li M; Seki Y; Freitas PH; Nagata M; Kojima T; Sultana S; Ubaidus S; Maeda T; Shimomura J; Henderson JE; Tamura M; Oda K; Liu Z; Guo Y; Suzuki R; Yamamoto T; Takagi R; Amizuka N
    J Electron Microsc (Tokyo); 2010; 59(3):227-36. PubMed ID: 20356821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTH/PTHrP receptor delays chondrocyte hypertrophy via both Runx2-dependent and -independent pathways.
    Guo J; Chung UI; Yang D; Karsenty G; Bringhurst FR; Kronenberg HM
    Dev Biol; 2006 Apr; 292(1):116-28. PubMed ID: 16476422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A common FGFR3 gene mutation is present in achondroplasia but not in hypochondroplasia.
    Stoilov I; Kilpatrick MW; Tsipouras P
    Am J Med Genet; 1995 Jan; 55(1):127-33. PubMed ID: 7702086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An activating Fgfr3 mutation affects trabecular bone formation via a paracrine mechanism during growth.
    Mugniery E; Dacquin R; Marty C; Benoist-Lasselin C; de Vernejoul MC; Jurdic P; Munnich A; Geoffroy V; Legeai-Mallet L
    Hum Mol Genet; 2012 Jun; 21(11):2503-13. PubMed ID: 22367969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.